Tatsunori Shimoi

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 501 citations

Medicine, Oncology, Pharmacology +17

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer

Roberto A. Leon‐Ferre, Sarah Flora Jonas, Roberto Salgado et al. · JAMA · 2024 · 199 citations · Full text

Medicine, Immunology, Oncology +15

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

Atsuko Kitano, Makiko Ono, Masayuki Yoshida et al. · ESMO Open · 2017 · 161 citations · Full text

Life Sciences, Immunology, Oncology +16

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Tatsunori Shimoi, Shigenori E. Nagai, Tetsuhiro Yoshinami et al. · Breast Cancer · 2020 · 76 citations · Full text

Medicine, Oncology, Breast Oncology +11

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Mitsuo Terada, Aki Ito, Yuichiro Kikawa et al. · Breast Cancer · 2023 · 61 citations · Full text

Medicine, Oncology, Breast Oncology +13